Poor response to intensive chemotherapy in de novo acute myeloid leukemia with trilineage myelodysplasia

K. Kuriyama; M. Tomonaga; T. Matsuo; T. Kobayashi; H. Miwa; S. Shirakawa; M. Tanimoto; K. Adachi; N. Emi; A. Hiraoka; N. Tominaga; K. Imai; N. Asou; K. Tsubaki; I. Takahashi; S. Minami; M. Yoshida; H. Murakami; K. Minato

doi:10.1111/j.1365-2141.1994.tb04827.x

Poor response to intensive chemotherapy in de novo acute myeloid leukemia with trilineage myelodysplasia

K. Kuriyama, M. Tomonaga, T. Matsuo, T. Kobayashi, H. Miwa, S. Shirakawa, M. Tanimoto, K. Adachi, N. Emi, A. Hiraoka, N. Tominaga, K. Imai, N. Asou, K. Tsubaki, I. Takahashi, S. Minami, M. Yoshida, H. Murakami, K. Minato

Research output: Contribution to journal › Article › peer-review

47 Citations (Scopus)

Abstract

The findings of morphologically dysplastic features in haemopoietic cells in de novo acute myeloid leukaemia (AML) has been named AML with trilineage myelodysplasia (AML/TMDS). We analysed the clinical data, karyotypes, and treatment outcomes of 230 de novo AML patients treated with the Japan Adult Leukaemia Study Group AML-87 protocol. 40 (17%) patients had AML/TMDS. Platelet count was significantly higher (P = 0.006) and bone marrow blasts were fewer (P = 0.01) in the AML/TMDS group than in the AML without TMDS. Abnormal karyotype was shown in 12/30 patients (40%) analysed. The complete remission (CR) rate for AML/TMDS was significantly lower than AML without TMDS (63% v 81%) (P = 0.01). The overall survival curves showed that the 40 patients with TMDS had a significantly worse survival than the 190 without TMDS (P = 0.0005). AML/TMDS also showed significantly worse disease-free survival (DFS) (P = 0.0001). Multivariate analysis revealed that the absence of TMDS in AML was the most significant factor in obtaining CR (P = 0.01) and a significant factor in predicting longer DFS (P = 0.04). Our data suggest that AML/TMDS responds poorly to intensive chemotherapy. Further study is required to determine the best treatment strategy for AML/TMDS and the biological differences between AML/TMDS and other types of AML.

Original language	English
Pages (from-to)	767-773
Number of pages	7
Journal	British Journal of Haematology
Volume	86
Issue number	4
DOIs	https://doi.org/10.1111/j.1365-2141.1994.tb04827.x
Publication status	Published - 1994
Externally published	Yes

Keywords

AML with trilineage myelodysplasia
FAB classification
dysplastic features
intensive chemotherapy
poor risk factor

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/j.1365-2141.1994.tb04827.x

Cite this

Kuriyama, K., Tomonaga, M., Matsuo, T., Kobayashi, T., Miwa, H., Shirakawa, S., Tanimoto, M., Adachi, K., Emi, N., Hiraoka, A., Tominaga, N., Imai, K., Asou, N., Tsubaki, K., Takahashi, I., Minami, S., Yoshida, M., Murakami, H., & Minato, K. (1994). Poor response to intensive chemotherapy in de novo acute myeloid leukemia with trilineage myelodysplasia. British Journal of Haematology, 86(4), 767-773. https://doi.org/10.1111/j.1365-2141.1994.tb04827.x

Kuriyama, K, Tomonaga, M, Matsuo, T, Kobayashi, T, Miwa, H, Shirakawa, S, Tanimoto, M, Adachi, K, Emi, N, Hiraoka, A, Tominaga, N, Imai, K, Asou, N, Tsubaki, K, Takahashi, I, Minami, S, Yoshida, M, Murakami, H & Minato, K 1994, 'Poor response to intensive chemotherapy in de novo acute myeloid leukemia with trilineage myelodysplasia', British Journal of Haematology, vol. 86, no. 4, pp. 767-773. https://doi.org/10.1111/j.1365-2141.1994.tb04827.x

@article{6b2ff02453aa4eec8c417d96b5b2a287,

title = "Poor response to intensive chemotherapy in de novo acute myeloid leukemia with trilineage myelodysplasia",

abstract = "The findings of morphologically dysplastic features in haemopoietic cells in de novo acute myeloid leukaemia (AML) has been named AML with trilineage myelodysplasia (AML/TMDS). We analysed the clinical data, karyotypes, and treatment outcomes of 230 de novo AML patients treated with the Japan Adult Leukaemia Study Group AML-87 protocol. 40 (17%) patients had AML/TMDS. Platelet count was significantly higher (P = 0.006) and bone marrow blasts were fewer (P = 0.01) in the AML/TMDS group than in the AML without TMDS. Abnormal karyotype was shown in 12/30 patients (40%) analysed. The complete remission (CR) rate for AML/TMDS was significantly lower than AML without TMDS (63% v 81%) (P = 0.01). The overall survival curves showed that the 40 patients with TMDS had a significantly worse survival than the 190 without TMDS (P = 0.0005). AML/TMDS also showed significantly worse disease-free survival (DFS) (P = 0.0001). Multivariate analysis revealed that the absence of TMDS in AML was the most significant factor in obtaining CR (P = 0.01) and a significant factor in predicting longer DFS (P = 0.04). Our data suggest that AML/TMDS responds poorly to intensive chemotherapy. Further study is required to determine the best treatment strategy for AML/TMDS and the biological differences between AML/TMDS and other types of AML.",

keywords = "AML with trilineage myelodysplasia, FAB classification, dysplastic features, intensive chemotherapy, poor risk factor",

author = "K. Kuriyama and M. Tomonaga and T. Matsuo and T. Kobayashi and H. Miwa and S. Shirakawa and M. Tanimoto and K. Adachi and N. Emi and A. Hiraoka and N. Tominaga and K. Imai and N. Asou and K. Tsubaki and I. Takahashi and S. Minami and M. Yoshida and H. Murakami and K. Minato",

year = "1994",

doi = "10.1111/j.1365-2141.1994.tb04827.x",

language = "English",

volume = "86",

pages = "767--773",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Poor response to intensive chemotherapy in de novo acute myeloid leukemia with trilineage myelodysplasia

AU - Kuriyama, K.

AU - Tomonaga, M.

AU - Matsuo, T.

AU - Kobayashi, T.

AU - Miwa, H.

AU - Shirakawa, S.

AU - Tanimoto, M.

AU - Adachi, K.

AU - Emi, N.

AU - Hiraoka, A.

AU - Tominaga, N.

AU - Imai, K.

AU - Asou, N.

AU - Tsubaki, K.

AU - Takahashi, I.

AU - Minami, S.

AU - Yoshida, M.

AU - Murakami, H.

AU - Minato, K.

PY - 1994

Y1 - 1994

N2 - The findings of morphologically dysplastic features in haemopoietic cells in de novo acute myeloid leukaemia (AML) has been named AML with trilineage myelodysplasia (AML/TMDS). We analysed the clinical data, karyotypes, and treatment outcomes of 230 de novo AML patients treated with the Japan Adult Leukaemia Study Group AML-87 protocol. 40 (17%) patients had AML/TMDS. Platelet count was significantly higher (P = 0.006) and bone marrow blasts were fewer (P = 0.01) in the AML/TMDS group than in the AML without TMDS. Abnormal karyotype was shown in 12/30 patients (40%) analysed. The complete remission (CR) rate for AML/TMDS was significantly lower than AML without TMDS (63% v 81%) (P = 0.01). The overall survival curves showed that the 40 patients with TMDS had a significantly worse survival than the 190 without TMDS (P = 0.0005). AML/TMDS also showed significantly worse disease-free survival (DFS) (P = 0.0001). Multivariate analysis revealed that the absence of TMDS in AML was the most significant factor in obtaining CR (P = 0.01) and a significant factor in predicting longer DFS (P = 0.04). Our data suggest that AML/TMDS responds poorly to intensive chemotherapy. Further study is required to determine the best treatment strategy for AML/TMDS and the biological differences between AML/TMDS and other types of AML.

AB - The findings of morphologically dysplastic features in haemopoietic cells in de novo acute myeloid leukaemia (AML) has been named AML with trilineage myelodysplasia (AML/TMDS). We analysed the clinical data, karyotypes, and treatment outcomes of 230 de novo AML patients treated with the Japan Adult Leukaemia Study Group AML-87 protocol. 40 (17%) patients had AML/TMDS. Platelet count was significantly higher (P = 0.006) and bone marrow blasts were fewer (P = 0.01) in the AML/TMDS group than in the AML without TMDS. Abnormal karyotype was shown in 12/30 patients (40%) analysed. The complete remission (CR) rate for AML/TMDS was significantly lower than AML without TMDS (63% v 81%) (P = 0.01). The overall survival curves showed that the 40 patients with TMDS had a significantly worse survival than the 190 without TMDS (P = 0.0005). AML/TMDS also showed significantly worse disease-free survival (DFS) (P = 0.0001). Multivariate analysis revealed that the absence of TMDS in AML was the most significant factor in obtaining CR (P = 0.01) and a significant factor in predicting longer DFS (P = 0.04). Our data suggest that AML/TMDS responds poorly to intensive chemotherapy. Further study is required to determine the best treatment strategy for AML/TMDS and the biological differences between AML/TMDS and other types of AML.

KW - AML with trilineage myelodysplasia

KW - FAB classification

KW - dysplastic features

KW - intensive chemotherapy

KW - poor risk factor

UR - http://www.scopus.com/inward/record.url?scp=0028304065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028304065&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.1994.tb04827.x

DO - 10.1111/j.1365-2141.1994.tb04827.x

M3 - Article

C2 - 7918070

AN - SCOPUS:0028304065

SN - 0007-1048

VL - 86

SP - 767

EP - 773

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 4

ER -

Poor response to intensive chemotherapy in de novo acute myeloid leukemia with trilineage myelodysplasia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this